HUB Organoids’ Post

🚨New Webinar Alert: Join Champions for our upcoming webinar 🚨 How to Design a Successful 3D Tumor Model Co-Culture Study Thursday September 5th, 2024 4pm CEST ◾10am EST ◾7am PST Save your spot: https://hubs.li/Q02LJyhH0 Join us for an insightful webinar with our immuno-oncology expert Dr. Mara Gilardi. This session will guide you through different aspects of designing an effective ex vivo 3D tumor model co-culture studies, focusing on model selection, donor choice, optimizing tumor-to-immune cell ratios, selecting controls, and choosing key readouts. Learn how to elevate your research with advanced 3D tumor models for more impactful oncology studies. #ImmunoOncology #tumorgraft3d #organoid #3dtumormodel #exvivo #CancerTreatment #OncologyInnovation #ImmunoTherapeutics #CancerTreatment ##CancerImmunotherapy #organoids #Coculture

Online!🏖️ Integrin-linked kinase-frizzled 7 interaction maintains #cancerstemcells to drive #platinumresistance in #ovariancancer --------------------- Platinum-based chemotherapy regimens are a mainstay in the management of ovarian cancer (OC), but emergence of chemoresistance poses a significant clinical challenge. The persistence of ovarian cancer stem cells (OCSCs) at the end of primary treatment contributes to disease recurrence. Here, Salvatore Condello et al. hypothesized that the extracellular matrix protects CSCs during chemotherapy and supports their tumorigenic functions by activating integrin-linked kinase (ILK), a key enzyme in drug resistance. For free👇 https://lnkd.in/dBPxks8J #Chemoresistance #Tumormicroenvironment IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

#cancerresearch #oncology #cancertreatment #metabolism #pancreaticcancer #Metabolic #reprogramming in malignant cells is a hallmark of cancer that relies on augmented glycolytic metabolism to support their growth, invasion, and metastasis. However, the impact of global #adipose #metabolism on tumor growth and the drug development by targeting adipose metabolism remain largely unexplored. Here we show that a therapeutic paradigm of drugs is effective for treating various cancer types by browning adipose tissues. Mirabegron, a clinically available drug for overactive bladders, displays potent anticancer effects in various animal cancer models, including untreatable cancers such as pancreatic ductal adenocarcinoma and hepatocellular carcinoma, via the browning of adipose tissues.

🔬 Functional Precision Medicine: Latest Insights  📚Functional precision oncology must beTwo groundbreaking studies shed light on using tumor-derived organoids for precision medicine in colorectal cancer: Ooft et al. (ESMO Open, 2021) conducted a trial on 61 patients, revealing organoid drug sensitivity but no clinical responses. Jensen et al. (J Exp Clin Cancer Res, 2023) studied 90 patients, reporting improved outcomes with individualized treatments based on organoid testing. 🛑Challenges remain, including organoid generation and timely result delivery. 🔮However, upcoming research by Cartry et al. offers promising solutions, paving the way for future clinical trials. 🔗Learn more by reading our latest published article on PDOs in functional precision medicine : Cartry et al. (PMID: 37880806) These findings mark a significant step in advancing personalized cancer care, emphasizing the need for ongoing innovation! #PrecisionMedicine #CancerResearch #OrganoidTechnology #ClinicalTrials

🔬 Exploring Advances in Solid Tumour Diagnostics 🔬 Findings : Concomitant KRAS and PIK3CA mutations Notes: KRAS mutations are prevalent in approximately 45% of colon adenocarcinomas, making them a key focus in understanding tumour behaviour and therapy resistance (Porru et al., 2018). KRAS mutation status serves as a predictive biomarker for the efficacy of EGFR-targeted therapies. Tumours with KRAS mutations often show resistance to anti-EGFR antibody therapies, either alone or in combination with chemotherapy (Van Cutsem et al., 2016). Moreover, the presence of concomitant KRAS and PIK3CA mutations in colorectal cancer is linked to more aggressive disease features and poorer overall survival outcomes (Luo et al., 2020). These insights underline the importance of precise molecular diagnostics in tailoring effective treatment strategies for patients. #CancerResearch #Oncology #MolecularDiagnostics #KRAS #PIK3CA #ColorectalCancer #PrecisionMedicine#

🚀 Exciting Advancement in the Liquid Biopsy Market! 🚀 Earlier this month the FDA has approved AKEEGA® (niraparib and abiraterone acetate) specifically for patients with BRCA-positive metastatic castration-resistant prostate cancer. This approval is coupled with the use of FoundationOne®Liquid CDx, a revolutionary liquid biopsy test from Foundation Medicine, which now enables identification of suitable patients for AKEEGA®. This cutting-edge liquid biopsy offers a less invasive alternative to traditional tissue biopsies, making the testing process more comfortable and accessible for patients. Key Highlights: FDA Approval Date: July 1, 2024 Indication: BRCA-positive metastatic castration-resistant prostate cancer Diagnostic Tool: FoundationOne®Liquid CDx liquid biopsy test This advancement underscores the significant strides we are making in precision medicine and personalized treatment plans. The integration of AKEEGA® with FoundationOne®Liquid CDx marks a pivotal step forward in providing tailored, effective treatments while reducing the physical burden on patients. #Oncology #FDAApproval #LiquidBiopsy #CancerResearch #PrecisionMedicine #FoundationMedicine #HealthcareInnovation #AKEEGA #ProstateCancer

We are delighted to announce that the Japanese Patent Office has granted patent protection for our PANURI project, titled “Novel Diagnostic Marker for Pancreatic Cancer.” Urteste continues to make significant progress in the field of diagnostics and is actively preparing to launch clinical trials for this groundbreaking project. As a company at the forefront of diagnostic innovation, we are developing 12 prototype tests targeting cancers responsible for nearly 70% of global cancer-related deaths. These include brain, breast, stomach, bile duct, ovarian, endometrial, kidney, colorectal, lung, liver, pancreatic, and prostate cancers. #pancreaticcancer #earlydetection #earlycancerdetection #urinetest #cancers #enzymesinurine #syntheticpeptides #diagnostictest #innovation

New!⛳️ TRF2 as novel marker of tumor response to #taxane-based therapy: from mechanistic insight to clinical implication ------------------------------- Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) – the most aggressive BC form – is refractory to endocrine and most of the target therapies. In this view, taxane-based therapy still represents the elective strategy for the treatment of this tumor. Telomeric Binding Factor 2 (TRF2), a key regulator of telomere integrity that is over-expressed in several tumors, including TNBC, has been recently found to plays a role in regulating autophagy, a degradative process that is involved in drug detoxification. Based on these considerations, Pasquale Zizza, Annamaria Biroccio et al. pointed, here, at investigating if TRF2, regulating autophagy, can affect tumor sensitivity to therapy. Look here👇 https://lnkd.in/drPMymCK #BreastCancer #TelomericBindingFactor #Autophagy #DrugSensitivity IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Tecelra (afamitresgene) by Adaptimmune the First for an Engineered Cell Therapy for Solid Tumors. The FDA approved Adaptimmune's Tecelra as a treatment for advanced cases of synovial sarcoma. It's the first engineered cell therapy approved for treating a solid tumor. Tecelra is a MAGE-A4–directed genetically modified autologous T‑cell immunotherapy administered as a one-time, single-dose treatment. It is indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA‑A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. https://lnkd.in/g9vNSRTp #HealthCare #Pharmacy #Tecelra #Adaptimmune #CellTherapy #TCell #Cancer #Sarcoma #Immunotherapy #SolidTumor

A Comparative Study: Proton Beam Therapy Vs Traditional Radiation for Prostate Cancer This research provides a thorough comparison between Intensity-Modulated Proton Therapy (IMPT) and Intensity-Modulated Radiation Therapy (IMRT) for the management of high-risk prostate cancer. This study meticulously examines the differential impact of these therapies on side effects that significantly affect patient quality of life. Key Highlights: ●Reduced Toxicities: IMPT significantly lowers gastrointestinal and genitourinary side effects compared to IMRT. ●Enhanced Patient Outcomes: IMPT improves the overall treatment experience, promoting quicker recoveries and less disruption to patients’ lives. ●Clinical Relevance: Supports broader use of IMPT in treating high-risk prostate cancer due to its superior safety and efficacy. ●Future Implications: Encourages further research into the long-term benefits and potential of IMPT in oncological care. Click here to read full article: https://lnkd.in/dphCyrcM Chilukuri Srinivas Sham Sundar Dayananda shamurailatpam #APCC #WinningOverCancer #ProtonTherapy #healthcare